Claims for Patent: 6,030,778

Summary for Patent: 6,030,778

Title:	Diagnostic assays and kits for body mass disorders associated with a polymorphism in an intron sequence of the SR-BI gene
Abstract:	The present invention is based at least in part on the discovery of a polymorphism in the human SR-BI gene which is genetically linked with a high body mass index. Accordingly, the invention provides diagnostic assays and kits for determining whether a subject has or is at risk of developing an abnormal body mass index, such as a high body mass.
Inventor(s):	Acton; Susan Laurene (Lexington, MA), Ordovas; Jose M. (Framingham, MA)
Assignee:	Millennium Pharmaceuticals, Inc. (Cambridge, MA)
Application Number:	08/890,979
Patent Claims:	1. A method for determining whether a human subject has, or is at risk of developing, an abnormally high body mass index, comprising determining the identity of nucleotide 54 of intron 5 of the SR-BI gene of the subject wherein the presence of a thymidine indicates that the subject has, or is at risk of developing an abnormally high body mass index. 2. A method of claim 1, wherein determining the identity of nucleotide 54 of intron 5 comprises contacting a nucleic acid of the subject with at least one probe or primer which is capable of hybridizing to an SR-BI gene. 3. A method of claim 2, wherein the probe or primer is capable of specifically hybridizing to a nucleic acid sequence comprising nucleotide 54 of intron 5. 4. A method of claim 3, wherein the probe or primer is capable of specifically hybridizing to a nucleic acid having a thymidine at position 54 of intron 5 of the SR-BI gene. 5. A method of claim 2, wherein the probe or primer has a nucleotide sequence from about 15 to about 30 nucleotides. 6. A method of claim 2, wherein the probe or primer is a single stranded nucleic acid. 7. A method of claim 2, wherein the probe or primer is labeled. 8. A method of claim 1, wherein determining the identity of nucleotide 54 of intron 5 is carried out by allele specific hybridization. 9. A method of claim 1, wherein determining the identity of nucleotide 54 of intron 5 is carried out by primer specific extension. 10. A method of claim 1, wherein determining the identity of nucleotide 54 of intron 5 is carried out by an oligonucleotide ligation assay. 11. A method of claim 1, wherein determining the identity of nucleotide 54 of intron 5 comprises performing a restriction enzyme site analysis. 12. A method of claim 11, wherein the restriction enzyme is an ApaI enzyme. 13. A method of claim 1, wherein determining the identity of nucleotide 54 of intron 5 is carried out by single-stranded conformation polymorphism. 14. A kit for determining whether a human subject has, or is at risk of developing, an abnormally high body mass index, comprising a probe or primer which is capable of specifically hybridizing to a region of a human SR-BI gene including nucleotide 54 of intron 5, wherein the presence of a thymidine at nucleotide 54 of intron 5 in the SR-BI gene of the subject indicates that the subject has, or is at risk of developing an abnormally high body mass index, and instructions for use. 15. A kit of claim 14, wherein the probe or primer is capable of hybridizing specifically to a region of the human SR-BI gene comprising a cytidine at nucleotide 54 of intron 5. 16. A kit of claim 4, wherein the probe or primer is capable of hybridizing specifically to a region of the human SR-BI gene comprising a thymidine at nucleotide 54 of intron 5. 17. A kit of claim 15, further comprising a second probe or primer which is capable of hybridizing specifically to a region of the human SR-BI gene comprising a thymidine at nucleotide 54 of intron 5. 18. A kit of claim 14, wherein the probe or primer has a nucleotide sequence from about 15 to about 30 nucleotides. 19. A kit of claim 14, wherein the probe or primer is a single stranded nucleic acid. 20. A kit of claim 14, wherein the probe or primer is labeled. 21. A method of claim 2, wherein the primer comprises a nucleotide sequence selected from the group consisting of: SEQ ID NO. 49 and SEQ ID NO. 50. 22. A method of claim 2, wherein the probe or primer is capable of hybridizing to SEQ ID NO. 9, SEQ ID NO. 26 or SEQ ID NO. 65 or the complement thereof. 23. A method of claim 2, wherein the probe or primer comprises a nucleic acid selected from the group consisting of: SEQ ID NO. 66, SEQ ID NO. 67, SEQ ID NO. 68 and SEQ ID NO. 69. 24. A method of claim 2, wherein the probe or primer comprises a nucleic acid selected from the group consisting of SEQ ID NO. 70, SEQ ID NO. 71, SEQ ID NO. 72 and SEQ ID NO. 73. 25. A kit of claim 14, wherein the probe or primer is capable of specifically hybridizing to SEQ ID NO. 9, SEQ ID NO. 26 or SEQ ID NO. 65 or the complement thereof. 26. A kit of claim 14, wherein the probe or primer comprises a nucleic acid selected from the group consisting of SEQ ID NO. 66, SEQ ID NO. 67, SEQ ID NO. 68 and SEQ ID NO. 69. 27. A kit of claim 14, wherein the probe or primer comprises a nucleic acid selected from the group consisting of: SEQ ID NO. 70, SEQ ID NO. 71, SEQ ID NO. 72 and SEQ ID NO. 73. 28. The method of claim 1, wherein the subject is a woman.

Details for Patent 6,030,778

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132	06/04/1986		2039-02-26
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132			2039-02-26
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	Injection	103132			2039-02-26